ClinicalTrials.gg
Active, not recruitingNCT06425302GOLSEEK-2Updated Jul 31, 2026

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

A Phase 2 interventional study of Golcadomide and Rituximab in Lymphoma, Follicular, sponsored by Celgene. Active, not recruiting at 56 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Lymphoma, Follicular by Bristol-Myers Squibb — 2 open to participants now, 6 under way, 1 of them phase 3. Lymphoma, Follicular · Bristol-Myers Squibb.

Enrollment
8th of 18
95 · median 61
Started
2024
with 4 others
Phase 2
2 of 23
none open now
Registered
18th of 23
by date

Among the 23 studies in Lymphoma, Follicular by Bristol-Myers Squibb, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2024, is one of 2 in phase 2, and was the 18th registered.

Lymphoma, Follicular

1,892 studies on the registry are indexed under Lymphoma, Follicular; 290 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

2 of the 23 studies in Lymphoma, Follicular by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Lymphoma, Follicular by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).

03

Conditions studied

  • Lymphoma, Follicular

Keywords

  • Follicular lymphoma
  • Grade 1-3a Follicular lymphoma
  • BMS-986369
  • CC-99282
  • Lymphoma
  • golcadomide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has confirmed Grade 1, 2 or 3a follicular lymphoma (FL) or classic FL. Formalin-fixed paraffin embedded (FFPE) from 1 year prior to screening is allowed. If more than 1 year has passed, then a fresh biopsy must be obtained to confirm the diagnosis.
  • Have no prior systemic treatment for follicular lymphoma. Prior radiation therapy or surgery for previously diagnosed stage I disease is acceptable.
  • Stage II to IV disease.
  • Deemed to need treatment by treating investigator. Reasons for treatment can include, but are not limited to, the following:.

    i) Bulky disease defined as:.

A. A nodal or extra nodal (except spleen) mass > 7cm in its greater diameter or, involvement of at least 3 nodal or extra nodal sites (each with a diameter greater than >3 cm).

ii) Presence of at least one of the following B symptoms:.

A. Fever (>38°C) of unclear etiology.

B. Night sweats.

C. Weight loss greater than 10% within the prior 6 months.

iii) Splenomegaly with inferior margin below the umbilical line.

iv) Any one of the following cytopenia due to lymphoma:.

A. \<100,000 cells/mm3 (100 x 109/L).

B. (ANC) \< 1,000 cells/mm3 (1.0 x 109/L).

C. \< 10g/dL (6.25 mmol/L).

v) Pleural or peritoneal serous effusion (irrespective of cell content).

vi) Any compressive syndrome (for example, but not restricted to ureteral, orbital, gastrointestinal).

Exclusion criteria

Exclusion Criteria

  • Clinical evidence of transformed lymphoma by investigator assessment.
  • Follicular Large Cell as per WHO 5th classification or Grade 3b follicular lymphoma as per WHO 4th classification.
  • Participant has any significant medical condition, active infection, laboratory abnormality, or psychiatric illness that would prevent the participation in the study.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    Rituximab + Chemotherapy

    R-CHOP (Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone) or Rituximab + Bendamustine

    Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone · Drug: Bendamustine

  • Experimental
    Golcadomide Dose 1 + Rituximab

    Drug: Golcadomide · Drug: Rituximab

  • Experimental
    Golcadomide Dose 2 + Rituximab

    Drug: Golcadomide · Drug: Rituximab

Interventions

  • Specified dose on specified days

    Also known as: CC-99282, BMS-986369

  • Specified dose on specified days

    Also known as: Mabthera

  • Specified dose on specified days

    Also known as: Endoxan

  • Specified dose on specified days

    Also known as: Caelyx, pegylated liposomal doxorubicin, PLD

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Number of participants who achieve complete metabolic response (CMR) as assessed by Lugano criteria 2014

    Golcadomide + Rituximab arms only

    Time frame: Up to approximately 12 months from participant randomization

Secondary outcomes

  1. Number of participants with Adverse Events (AEs) as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) criteria, v.5.0

    Time frame: Up to 28 days after last dose

  2. Number of participants with Treatment-emergent AEs (TEAEs) as assessed by the NCI CTCAE criteria, v.5.0

    Time frame: Up to 28 days after last dose

  3. Best Overall Response (OR)

    Defined as achieving CMR or partial metabolic response (PMR) based on Lugano criteria 2014

    Time frame: Up to approximately 12 months from participant randomization

  4. Duration of Response (DoR)

    Defined as time from first confirmed response (Complete Response (CR) or Partial Response (PR)) to disease progression, start of new anti-lymphoma therapy, or death

    Time frame: Up to approximately 3 years after randomization of the last participant

  5. Complete Response at 30 months (CR30)

    Defined as achieving CR based on Lugano criteria at 30 months from randomization

    Time frame: At approximately 30 months from randomization

  6. Complete Metabolic Response at 6 months from the randomization (CMR6)

    Defined as achieving CMR based on Lugano criteria 2014 at 6 months from randomization

    Time frame: At approximately 6 months from randomization

  7. Complete Metabolic Response at 12 months from the randomization (CMR12)

    Defined as achieving CMR based on Lugano criteria 2014 at 12 months from randomization

    Time frame: At approximately 12 months from randomization

  8. Progression Free Survival (PFS)

    Defined as time from date of randomization to first occurrence of disease progression or death from any cause

    Time frame: Up to approximately 3 years from randomization of last participant

  9. Overall Survival (OS)

    Defined as time from date of randomization to death from any cause

    Time frame: Up to approximately 3 years from randomization of last participant

  10. Number of participants who achieve CMR as assessed by Lugano criteria 2014

    Rituximab + Chemotherapy arm only

    Time frame: Up to approximately 6 months from randomization

07

Study locations

56 sites
  • Local Institution - 0152
    Birmingham, Alabama 35294-3300, United States
  • Local Institution - 0055
    Anchorage, Alaska 99508, United States
  • Local Institution - 0180
    Phoenix, Arizona 85054, United States
  • Local Institution - 0190
    Tucson, Arizona 85711, United States
  • Local Institution - 0035
    San Francisco, California 94143, United States
  • Local Institution - 0022
    Washington D.C., District of Columbia 20007, United States
  • Local Institution - 0209
    Fort Myers, Florida 33901, United States
  • Local Institution - 0005
    Jacksonville, Florida 32224, United States
  • Local Institution - 0210
    St. Petersburg, Florida 33705, United States
  • Local Institution - 0026
    Tampa, Florida 33606, United States
  • Local Institution - 0208
    West Palm Beach, Florida 33401, United States
  • Local Institution - 0019
    Westwood, Kansas 66205, United States
  • Local Institution - 0031
    Rochester, Minnesota 55905, United States
  • Local Institution - 0111
    Henderson, Nevada 89074, United States
  • Local Institution - 0183
    Hackensack, New Jersey 07601, United States
  • Local Institution - 0052
    Salt Lake City, Utah 84106, United States
  • Local Institution - 0201
    Norfolk, Virginia 23502, United States
  • Local Institution - 0202
    Seattle, Washington 98109, United States
  • Local Institution - 0046
    Liverpool, New South Wales 2170, Australia
  • Local Institution - 0070
    South Brisbane, Queensland 4101, Australia
  • Local Institution - 0181
    Traralgon, Victoria 3844, Australia
  • Local Institution - 0061
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • Local Institution - 0060
    Rio de Janeiro, 22250-905, Brazil
  • Local Institution - 0058
    São Paulo, 04543-000, Brazil
  • Local Institution - 0056
    São Paulo, 05652-900, Brazil
  • Local Institution - 0064
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution - 0205
    Chicoutimi, Quebec G7H 5H6, Canada
  • Local Institution - 0049
    Santiago, Santiago Metropolitan 7500921, Chile
  • Local Institution - 0050
    Santiago, Santiago Metropolitan 7580206, Chile
  • Local Institution - 0101
    Saint-Cloud, Hauts-de-Seine 92210, France
  • Local Institution - 0103
    Lille, Nord 59000, France
  • Local Institution - 0121
    Poitiers, Vienne 86021, France
  • Local Institution - 0118
    Paris, 75010, France
  • Local Institution - 0197
    Regensburg, Bavaria 93049, Germany
  • Local Institution - 0188
    Chemnitz, Saxony 09116, Germany
  • Local Institution - 0189
    Dresden, 01307, Germany
  • Local Institution - 0198
    Rome, Lazio 00133, Italy
  • Local Institution - 0179
    Rozzano, Milano 20089, Italy
  • Local Institution - 0076
    Bologna, 40138, Italy
  • Local Institution - 0075
    Naples, 80131, Italy
  • Local Institution - 0187
    Skórzewo, Greater Poland Voivodeship 60-185, Poland
  • Local Institution - 0186
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-168, Poland
  • Local Institution - 0185
    Warsaw, Masovian Voivodeship 01-748, Poland
  • Local Institution - 0100
    Busan, Pusan-Kwangyǒkshi 49241, South Korea
  • Local Institution - 0085
    Seoul, Seoul-teukbyeolsi [Seoul] 03080, South Korea
  • Local Institution - 0086
    Seoul, Seoul-teukbyeolsi [Seoul] 06351, South Korea
  • Local Institution - 0196
    Palma, Balears [Baleares] 07120, Spain
  • Local Institution - 0192
    Valencia, Valenciana, Comunitat 46017, Spain
  • Local Institution - 0191
    Madrid, 28040, Spain
  • Local Institution - 0094
    Kaohsiung City, 807, Taiwan
  • Local Institution - 0092
    Kaohsiung City, 83301, Taiwan
  • Local Institution - 0123
    Taipei, 10002, Taiwan
  • Local Institution - 0175
    Southampton, Hampshire SO16 0YD, United Kingdom
  • Local Institution - 0112
    Canterbury, Kent CT1 3NG, United Kingdom
  • Local Institution - 0115
    Edinburgh, Midlothian EH4 2XU, United Kingdom
  • Local Institution - 0105
    Nottingham, NG5 1PB, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Jun 2026, 21 months.

Of 48 industry-sponsored phase 2 interventional studies under Lymphoma, Follicular, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 52. This study's 21 months is below that.

Counting every sponsor, half of 199 studies reached it within 57 months; a quarter within 31 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2024
First posted
May 22, 2024
StartActual
Aug 30, 2024
Primary completionActual
Jun 19, 2026
CompletionEst.
Nov 27, 2028
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06425302
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
May 22, 2024
Start date
Aug 30, 2024
Primary completion
Jun 19, 2026
Completion
Nov 27, 2028 (estimated)
Last update
Jul 31, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Golcadomide

Start the discussion